Alkermes sees revenues rise by 185%

Alkermes — the US biopharmaceutical group — has witnessed the first benefits of its takeover of Elan’s Athlone-based drug delivery arm, with third-quarter revenues rising by more than 185%.

The Nasdaq-quoted company — Specialising in treatments for diseases affecting the central nervous system — said yesterday that revenues grew to $126 million (€96m) over the three months to the end of December; up by more than 185% on the same quarter in 2010.

Earnings before interest, tax, depreciation and amortisation grew to $29.7m. The figures covered the first full quarter following Alkermes’ September merger with Elan Drug Technologies (EDT).